Viral Infections: Oncogenic HPV, Genital Herpes, and Hepatitis B

High-Risk Oncogenic Human Papillomavirus (HPV)

The human papillomavirus enters the body through tissue microlesions caused during intimate contact, reaching the basal layer of the mucosal epithelium. After cellular penetration, the viral genome integrates into the host’s nucleus.

Variants with high oncogenic potential—predominantly types 16 and 18—synthesize the viral oncoproteins E6 and E7.

These molecules systematically block primary tumor suppressor proteins, such as p53, which regulate the cell cycle and DNA repair.

As a result, infected cells lose their ability to undergo programmed cell death, leading to uncontrolled proliferation and the accumulation of chromosomal abnormalities.

Over the course of a silent process lasting ten to fifteen years, this ongoing cellular damage progresses from mild dysplasia to invasive neoplasms in the cervix, vulva, anal region, and oropharyngeal cavity.

Genital Herpes and Mechanisms of Viral Latency

Infection with the herpes simplex virus, caused by viral types 1 or 2, is transmitted through direct exposure to mucous membranes or active lesions.

The pathogen enters epithelial cells, causing outbreaks characterized by painful erythematous vesicles, which subsequently ulcerate.

Following the primary symptomatic phase, the viral agent migrates along sensory nerve fibers until it establishes permanent somatic latency in the dorsal root ganglia of the peripheral nervous system.

The virus remains dormant until triggering factors such as stress, immunosuppression, or hormonal imbalances reactivate its replication, leading to symptomatic recurrences.

Although the disease is incurable due to this neurotropic integration, suppressive treatment with specific antiviral drugs shortens the duration of clinical episodes, alleviates local discomfort, accelerates healing, and significantly reduces the risk of transmission to sexual partners.

Hepatitis B Virus (HBV) and Liver Complications

The hepatitis B virus is a highly infectious pathogen that spreads through parenteral routes and via bodily fluids during unprotected sexual intercourse.

Upon entering the bloodstream, the agent exhibits a specific tropism toward hepatocytes, triggering an immune-mediated inflammatory response that progressively damages liver tissue.

Most infections in adults are asymptomatic or mild, but a percentage of patients develop acute symptoms including jaundice, asthenia, and dark urine.

The primary clinical severity stems from the agent’s persistence in the body, leading to a chronic condition that increases the long-term risk of cirrhosis or hepatocellular carcinoma.

Unlike other viral infections, a highly effective prophylactic vaccine is available to immunize the population, in addition to antiviral treatments aimed at controlling viral replication and preventing irreversible parenchymal damage.

Summary

Oncogenic human papillomavirus infects basal cells and integrates its genetic material, expressing viral proteins that inactivate tumor-suppressor mechanisms. This alteration promotes abnormal cell division, leading to carcinogenic processes.

The herpes simplex virus causes ulcerative epithelial outbreaks and subsequent permanent neurological latency in sensory ganglia. Although it is an incurable infection with periodic reactivations, antiviral drug therapy successfully suppresses symptoms and transmission.

Hepatitis B infects hepatocytes through sexual or parenteral transmission and can become chronic, leading to cirrhosis or hepatocellular carcinoma. Prevention relies on effective vaccination, while antiviral drugs control viral replication.